Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vinius University currently manages a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The portfolio shows a concentrated prosecution landscape with 1 pending office action distributed across 1 distinct examiner. This indicates a specific point of contact within the patent office for the current workload.
The busiest examiner for this portfolio is SALMON, KATHERINE D, who is responsible for 1 busiest examiner pending office action. Because the total pending office actions count is 1, this specific examiner handles the entirety of the university's active prosecution matters. This concentration in 1 distinct art unit suggests a focused technical scope for the pending applications within the Biotechnology & Pharmaceuticals sector.
Practitioners should note that with only the 1 distinct examiner involved, the prosecution strategy is currently dependent on the individual tendencies of SALMON, KATHERINE D. The presence of the 1 distinct art unit further confirms that the portfolio's active components are not currently diversified across different examination groups at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17628242 | CHARACTERIZATION OF PROSTATE CANCER USING DNA METHYLATION ASSAY SYSTEM | SALMON, KATHERINE D | 140d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17628242 | CHARACTERIZATION OF PROSTATE CANCER USING DNA METHYLATION ASSAY SYSTEM | SALMON, KATHERINE D | 140d overdue |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17628242 | CHARACTERIZATION OF PROSTATE CANCER USING DNA METHYLATION ASSAY SYSTEM | SALMON, KATHERINE D | 1682 | §101§112 | Final Rejection | 140d overdue | Pending | Jan 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial